Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Pycnogenol and Saccharomyces Boulardii are closely matched across evidence, studies, and safety.
Verdict
Likely helps
12 of 15 studies with measurable effects showed benefit.
Top outcomes
Verdict
Likely helps
13 of 15 studies with measurable effects showed benefit.
Top outcomes
50-200mg
With meals
Pycnogenol brand (standardized to 65-75% procyanidins)
250-500mg (5-10 billion CFU) daily
With or without food, At least 2 hours away from antifungals
Capsules (lyophilized)
4-8 weeks
4-8 weeks
6-12 weeks
During use
1-3 days
1-2 weeks
Phlebotonics for venous insufficiency
The Cochrane database of systematic reviews (2020) · Meta analysis · n=7690
Pooled data suggest that phlebotonics probably increase adverse events slightly, compared to placebo (RR 1.14, 95% CI 1.02 to 1.27; 37 studies; 5789 participants; moderate-certainty evidence).
Pine bark (Pinus spp.) extract for treating chronic disorders
The Cochrane database of systematic reviews (2020) · Meta analysis · n=1641
In a mixed group of participants with type 1 and type 2 DM we do not know whether pine bark extract decreases HbA1c (MD -0.20 %, 95% CI -1.83 to 1.43; one study; 67 participants; very low-certainty evidence).
Effect of pycnogenol supplementation on blood pressure: A systematic review and meta-analysis of clinical trials
Phytotherapy research : PTR (2020) · Meta analysis · n=922
Pooled analysis suggested that pycnogenol supplementation can reduced systolic blood pressure (SBP) of (-3.22 mmHg; 95% CI [-5.52, -0.92]) and diastolic blood pressure (DBP; -1.91 mmHg; 95% CI [-3.64, -0.18]).
Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication of Helicobacter pylori: a meta-analysis
Frontiers in cellular and infection microbiology (2025) · Meta analysis · n=5036
S. boulardii supplementation in traditional eradication therapy significantly improves the H. pylori eradication rate and reduces the total adverse effects and incidence of diarrhea, bloating, constipation, and nausea.
Probiotics for treating acute infectious diarrhoea
The Cochrane database of systematic reviews (2020) · Meta analysis · n=12127
Effect size was similar in the sensitivity analysis and marked heterogeneity persisted.
The use of probiotics and prebiotics in decolonizing pathogenic bacteria from the gut; a systematic review and meta-analysis of clinical outcomes
Gut microbes (2024) · Meta analysis · n=2871
This review aims to analyze available evidence from human-controlled trials to determine the effect size of probiotic interventions in decolonizing AMR pathogenic bacteria from the gut.
Based on meta-analyses showing modest reductions in systolic (-3.22 mmHg) and diastolic (-1.91 mmHg) blood pressure. Evidence quality varies across studies and effect sizes are relatively small.
Based on multiple meta-analyses showing 1.1-1.6 day reduction in diarrhea duration. Effect size appears to plateau at standard therapeutic doses. Limited data on doses above 20 billion CFU.
AI-estimated from published studies. Interpret as directional guidance.
Both Pycnogenol and Saccharomyces Boulardii are closely matched — the best choice depends on your specific health goals.
For reduce inflammation, Saccharomyces Boulardii has a higher relevance score (90 vs 80).
No known interactions between Pycnogenol and Saccharomyces Boulardii have been documented in our database. However, always consult a healthcare provider before combining supplements.